Reason #3: A Great End To A Great Investment
There have been plenty of investors that saw value in RARX early on. The company’s assets have shown promise every step of the way.
While there have been ups and downs, the strong work that the company has done to bring a new treatment option for patients with gMG is leading to a big payoff in the end.
At the end of the day, this is exactly the type of thing that biotechnology investors are investing for. Get in while treatments are being developed. Then as late stages come into play, bigger companies with deep pockets are willing to pay substantial premiums in an effort to control wider markets.
That’s exactly what happened here. The company showed incredibly positive results in a difficult indication. As such the value of the company was too much to pass up, leading to a large-value acquisition.
For those that have been hanging onto RARX, congratulations. You just got a big payday!
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!